METASTATIC ESOPHAGEAL ADENOCARCINOMA
Clinical trials for METASTATIC ESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC ESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could an immunotherapy boost help fight stomach cancer?
Disease control Recruiting nowThis clinical trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or esophageal cancer live longer. The study includes 224 adults whose cancer has a specific marker (PD-L1 CPS…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
Supercharged immune cells take on stubborn esophageal cancer
Disease control Recruiting nowThis early-stage trial tests a new treatment for advanced esophageal cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) from donated cord blood that are designed to recognize and attack cancer cells carrying tw…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New chemo combo tested to extend life in Hard-to-Treat stomach and esophageal cancers
Disease control Recruiting nowThis study tests whether a stronger chemotherapy mix (mFOLFIRINOX) works better than the standard mix (FOLFOX) for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. Some participants also receive the immunotherapy dru…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug combo aims to shrink tough stomach cancers
Disease control Recruiting nowThis Phase 2 trial tests whether adding the immunotherapy drug ivonescimab to standard chemotherapy can improve tumor shrinkage in people with advanced or metastatic stomach or gastroesophageal cancer. About 88 participants will receive treatment every two weeks. The main goal is…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could a heart drug boost cancer treatment? new trial tests propranolol with chemo and immunotherapy
Disease control Recruiting nowThis phase 2 trial is testing whether adding propranolol, a common beta-blocker used for heart conditions, to standard chemotherapy and pembrolizumab (an immunotherapy) can improve treatment response in people with advanced esophageal or gastroesophageal junction cancer that cann…
Matched conditions: METASTATIC ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC